Protagenic Therapeutics, Inc.

149 Fifth Avenue

New York, NY 10010

June 21, 2021

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Re: Protagenic Therapeutics, Inc. Registration Statement on Form S-3 Filed June 21, 2021 File No. 333-256790

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Protagenic Therapeutics, Inc. (the “Company”), the undersigned hereby requests that the Company’s Registration Statement on Form S-3 (File No. 333-256790) filed with the U.S. Securities and Exchange Commission (the “Commission”) on June 21, 2021 (the “Registration Statement”), be declared effective on June 23, 2021, at 9:00 a.m., Eastern Standard Time, or as soon as practicable thereafter.

Very truly yours,
PROTAGENIC THERAPEUTICS, INC.
By:	/s/ Alexander K. Arrow
	Alexander K. Arrow Chief Financial Officer

cc: Dean Colucci, Duane Morris LLP